Phase Forward (ticker: PFWD, exchange: NASDAQ Global Market (.O))
News Release -
Phase Forward to Participate in DIA Workshop for Clinical Data Management in Japan, January 29-30
Phase Forward to Exhibit, Present Sessions on EDC and Data Repositories
WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 20, 2009--Phase
Forward (NASDAQ: PFWD), a leading provider of data management
solutions for clinical trials and drug safety, will participate in the 12th
Annual Drug Information Association (DIA) Workshop for Clinical Data
Management, January 29-30 at the Tower Hall Funabori in Tokyo, Japan.
On Thursday, January 29, at 4:45 p.m. local time, company CTO Tim
Rochford will discuss "Repository Families: Avoiding Dysfunctional
Relationships." Mr. Rochford will contrast essential design requirements
of cross-repository analysis activities with affordances offered by
underlying technology approaches.
Vice president of global CRO partnerships, Mike Davies will lead
a session titled, "Building a Strong EDC Foundation through the Power of
Partnership" on Friday, January 30, at 4:30 p.m. local time. Leveraging
customer data and experiences, Mr. Davies will discuss how the role
of EDC, from technology to services, evolves over time and the critical
role partnerships play to success.
The company will also showcase its EDC, safety management, Phase I and
interactive response technologies at booths 7 and 8.
Members of the media interested in speaking with Phase Forward at this
event should contact Maria Sumner at +44 1628 640743 or email@example.com.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers proven
solutions for electronic data capture (InForm(TM)), phase I clinic
automation (LabPas(TM)), clinical data management (Clintrial(TM)), clinical
trials signal detection (CTSD(TM)), strategic pharmacovigilance (Empirica
Signal(TM)) and Signal Management, adverse event reporting (Empirica
Trace(TM)), applied data standards (WebSDM(TM)) and Web-integrated interactive
response technologies (Clarix(TM)). In addition, the company provides
services in the areas of application implementation, hosting and
validation, data integration, business process optimization, safety data
management and industry standards. Phase Forward's products and services
have been utilized in over 10,000 clinical trials involving more than
1,000,000 clinical trial study participants at over 280 organizations
and regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and
Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International,
Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research
Institute, Servier, Tibotec and the U.K. Medicines and Healthcare
Products Regulatory Agency. Additional information about Phase Forward
is available at www.phaseforward.com.
CONTACT: Phase Forward
Maria Sumner, +44 1628 640743
Source: Phase Forward